← Back to Search

Virus Therapy

HCVax for Chronic Hepatitis C

Phase 1

Waitlist Available

Research Sponsored by GeneCure Biotechnologies

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 40 weeks

Awards & highlights

Study Summary

This trial is to see if a new HCV immunotherapy is safe and if it causes an immune response in patients with chronic HCV.

Eligible Conditions

Chronic Hepatitis C

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 40 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~40 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 40 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To evaluate the safety of a therapeutic HCV vaccine in chronic HCV patients

Secondary outcome measures

To evaluate the immunogenicity of a therapeutic HCV vaccine in chronic HCV patients

Virologic response

Trial Design

2Treatment groups

Experimental Treatment

Group I: Low dose groupExperimental Treatment1 Intervention

Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.

Group II: High dose groupExperimental Treatment1 Intervention

Chronic HCV patients. Fifteen subjects will receive 1.0 ml of high dose vaccine at weeks 0, 8 and 16 through subcutaneous route.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

GeneCure BiotechnologiesLead Sponsor

2 Previous Clinical Trials

62 Total Patients Enrolled

Media Library

HCVax (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04318379 — Phase 1

Chronic Hepatitis C Research Study Groups: Low dose group, High dose group

Chronic Hepatitis C Clinical Trial 2023: HCVax Highlights & Side Effects. Trial Name: NCT04318379 — Phase 1

HCVax (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04318379 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially qualify to engage in this clinical experiment?

"To be eligible for this research, individuals must have hepatitis and fall within the age range of 18 to 60. A total of 30 participants will partake in the trial."

Answered by AI

Does this research endeavor include individuals aged sixty and above?

"According to the criteria for participation, prospective patients must be aged 18-60. Those under 18 are eligible for 27 different studies and those over 65 can apply for 237 trials."

Answered by AI

Are any new participants being welcomed into this research endeavor?

"According to the records available on clinicaltrials.gov, this research study is still accepting patient applications. The protocol was initially unveiled in April of 2021 and has been revised most recently at the end of September that same year."

Answered by AI

How many individuals have been conscripted to take part in this research?

"Affirmative. Research hosted on clinicaltrials.gov indicates that this scientific investigation, which first appeared online on April 20th 2021, is currently searching for participants. 30 patients need to be sourced from two different medical facilities."

Answered by AI